Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266058 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study Between Antimalarial and Anti-HIV Medications
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00266058 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 33 participants.
The verdict
NCT00266058, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether taking certain anti-HIV medicines with certain antimalarial medicines affects the amount of the medicines in the blood. The study medicines that will be used are artemether/lumefantrine (antimalarial medication) and lopinavir/ritonavir or efavirenz (anti-HIV medications). Artemether/lumefantrine is not approved by the United States Food and Drug Administration (FDA) but is recommended as standard of care medical treatment for malaria in Africa and Asia. Lopinavir/ritonavir and efavirenz are approved by the FDA. Artemether/lumefantrine and lopinavir/ritonavir or efavirenz may need to be used together to treat children in Africa and Asia. We seek to learn about whether or not the use of these medicines together results in a change in blood levels of any of these medicines. The information obtained from this study will help doctors to provide a better treatment to children and adults with malaria and HIV.
Interventions
- DRUG Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00266058
The ClinicalTrials.gov registry entry for NCT00266058 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine is the first listed.
NCT00266058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00266058 about?
NCT00266058 is a clinical study titled "Drug Interaction Study Between Antimalarial and Anti-HIV Medications". The purpose of this study is to find out whether taking certain anti-HIV medicines with certain antimalarial medicines affects the amount of the medicines in the blood. The study medicines that will be used are artemether/lumefantrine (antimalarial medication) and lopinavir/ritonavir or efavirenz (...
What is the current status of trial NCT00266058?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2005-12. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00266058?
The interventions under investigation include: Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine (DRUG).
Who is sponsoring clinical trial NCT00266058?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.